Kaluza 流式細胞分析軟體

Kaluza 分析旨在簡單、有效、快速地分析多色的數據。四個簡單的控制面板提供了對數據各個方面的訪問。

 根據需要在儘可能多的計算機上安裝軟體,並使用適合您需要的許可選項控制訪問。可以使用多種單用戶和多用戶許可證。瞭解更多關於 Kaluza 分析軟體設計的原理

 

歡迎體驗我們 30 天的免費試用版!

*僅供工業和科研使用,不用於臨床診斷

Features

更多分析,更少點擊

  • 平移以方便地定位圖區域內中的數據
  • 放大/縮小功能可放大關注區域
  • 創新的圓形菜單可減少鼠標點擊
  • 靈活的工作面設計可減少混亂
  • 每個分析有多種報告佈局
  • 複製/粘貼多選圖至其他應用
  • 對大文件進行更快刷新   
  •    

兼容現有實驗室平台

  • 直接從瀏覽器進行多文件載入,批處理
  • 支持 Windows 7 和 WIN 7 64-bit、WIN 8、WIN 8.1 和 WIN 10
  • 通過各種 FCS 文件改進工作流程
  • 可兼容外語翻譯,包括簡體中文和日文

通過創新圖類型直接查看數據

用除傳統散點圖、直方圖和等高線圖以外的多種圖類型形象化處理您的數據。

  • 用樹圖快速並方便地分類細胞
  • 帶門控雷達圖
    • 為何您可看到 3D 時卻看到了 2D?
  • 疊加直方圖,用於在一個視圖中比較多個圖
  • 疊加密度圖和等高線圖

分析數百萬個細胞、而非數千個

可實時處理多達 10,000,000 次事件!用新的方式與您的數據互動。用 Kaluza 專利技術在您修改門控時查看圖和統計變化。

  • 實時與大數據集合一起工作
  • 輕鬆進行複雜的分析
  • 最大化您對計算處理器的投資

Explore Kaluza Models

Content and Resources

Filter by:
Resource Type
Automating Flow Cytometry Brochure Mitigating sources of variability begins during assay design, continues during analytical method development, and through process monitoring
Kaluza Analysis Software Brochure Kaluza Analysis Software allows access to data analysis of large files resulting from complex color analysis.
Offline Flow Cytometry Analysis Software: Importance of Scaling and Data Visualization Learn about the flow cytometry open platform data structure and how it facilitates for robust offline analysis
Whitepaper: Kaluza Analysis Tree Plots offer a fast and comprehensive overview of multi-color flow cytometry data Introduces the Tree Plot as a supervised approach for comprehensive deconvolution of flow cytometry data, bridging the gap between manual gating and unsupervised computational analysis
Using Standardized Dry Antibody Panels for Flow Cytometry in the Assessment of Altered Immune Profiles in Response to SARS-CoV2 Infection In order to identify early indicators of disease severity in SARS-CoV2-infection, the proportions of well-established immune cell phenotypes have been subject to extensive research, utilizing flow cytometry as a core technology1-3. In order to ensure comparable and consistent results in the massively multi-institutional research setting of a global pandemic, the use of standardized antibody panels and procedures, as demonstrated by The ONE Study4-6, is a promising approach that also can lower technical barriers

Technical Documents